
A close-up of hands holding a tablet and a pen

Description automatically generated**U.S. Artificial Intelligence in Cancer Diagnostics Market**

According to Intelli, U.S. Artificial Intelligence in Cancer Diagnostics Market Size was valued at USD 121.1 Million in 2024 and is projected to reach USD 579.85 Million by 2032, growing at a CAGR of 22.15% from 2025 to 2032.



Cancer remains one of the leading causes of death worldwide, with early detection being critical for effective treatment and improved survival rates. In recent years, Artificial Intelligence (AI) has emerged as a game-changer in the field of cancer diagnostics, revolutionizing the way we detect, analyze, and understand cancer. AI systems learn from vast amounts of data, identifying patterns and improving their performance over time through machine learning and deep learning techniques. By leveraging vast amounts of medical data, including imaging, pathology slides, and genomic information, AI algorithms can identify patterns that are often imperceptible to the human eye. These AI systems also enhance diagnostic accuracy by detecting patterns and abnormalities that often go unnoticed by human clinicians, enabling earlier cancer detection and guiding more personalized treatment approaches. AI-powered tools are enabling clinicians to make faster, more informed decisions, ushering in a new era of personalized medicine and early intervention.

**U.S. Artificial Intelligence in Cancer Diagnostics Market Definition**

**​**The U.S. Artificial Intelligence in Cancer Diagnostics Market refers to the sector that focuses on the development, integration, and application of AI technologies to enhance the detection, diagnosis, and treatment planning of cancer. This market includes a variety of AI-powered technologies such as machine learning algorithms, deep learning networks, and natural language processing systems, developed to interpret complex medical data like imaging scans, pathology slides, and genomic profiles.

**U.S. Artificial Intelligence in Cancer Diagnostics Market Overview**

The U.S. Artificial Intelligence (AI) in Cancer Diagnostics Market is experiencing a significant surge, driven by technological advancements, increasing cancer prevalence, and substantial investments in AI-driven healthcare solutions. This growth is further bolstered by government initiatives, such as the U.S. government's launch of AI.gov, aimed at fostering the regulation, development, and application of AI in various sectors, including healthcare. Additionally, substantial private investments are fueling the market's expansion. For instance, Tempus AI, a Chicago-based genetic testing firm specializing in AI-powered genomic diagnostics, has garnered positive attention from Wall Street analysts, A close-up of hands holding a tablet and a pen

Description automatically generatedwith forecasts predicting significant revenue growth and profitability in the coming years. Alongside public backing, private investments are playing a crucial role in driving market growth. A notable example is Tempus AI, a Chicago-based company focused on AI-powered genomic diagnostics, which has attracted favorable attention from Wall Street analysts. With its growing ability to improve diagnostic precision and support personalized treatment approaches, AI is rapidly reshaping cancer diagnostics in the U.S. The market is on a strong growth trajectory, offering the potential for better patient outcomes and a significant transformation in the way cancer is detected and treated.

**U.S. Artificial Intelligence in Cancer Diagnostics Market Segmentation**

The U.S. Artificial Intelligence in Cancer Diagnostics Market is segmented based on Component, cancer types and End-Use. It reflects the diverse applications and growing consumer base.

**U.S. Artificial Intelligence in Cancer Diagnostics Market, BY Component**

* **Software solution**
* **Hardware**
* **Services**

The U.S. Artificial Intelligence in Cancer Diagnostics Market is segmented into software solutions, hardware, and services, each playing a critical role in advancing cancer care. Software solutions lead the market, driving innovation with advanced algorithms for image analysis, pattern recognition, and predictive diagnostics. Hardware components, such as AI-enabled imaging devices and processing units, give the necessary infrastructure to support these intelligent systems. It ensures high-speed data processing and real-time diagnostics. Meanwhile, services including system integration, consulting, and support—ensure seamless implementation and ongoing optimization of AI tools in clinical settings.

**U.S. Artificial Intelligence in Cancer Diagnostics Market, By Cancer Types**

* **Brain tumor**
* **Breast Cancer**
* **Lung Cancer**
* **Colorectal Cancer**
* **Prostate Cancer**
* **Others**

A close-up of hands holding a tablet and a pen

Description automatically generatedIn the U.S., the integration of AI in brain tumor diagnostics is transforming how clinicians detect, classify, and monitor these complex conditions. Diagnosing brain tumors is particularly challenging due to their wide range of subtypes and their proximity to vital brain structures. The brain tumor segment is projected to experience the highest CAGR during the forecast period, reflecting its rapidly increasing adoption of AI-driven diagnostic technologies. AI-powered imaging technologies, especially those utilizing deep learning and machine learning algorithms are significantly improving both the speed and precision of tumor detection by conducting advanced analyses of MRI and CT scan data. Additionally, AI models are being developed to integrate radiology, pathology, and genomic data, enabling a comprehensive and personalized diagnostic approach. AI is playing a pivotal role in advancing breast cancer diagnostics, offering new levels of accuracy, efficiency, and early detection. According to the American Cancer Society, breast cancer is the most commonly diagnosed cancer among women in the U.S., aside from skin cancer, impacting roughly one in three women. Globally, the burden is even more significant. AI-powered tools are now being integrated into diagnostic workflows to enhance the interpretation of mammograms, ultrasounds, and MRIs. AI is helping reduce the workload on radiologists by automating the analysis process and prioritizing high-risk cases for review. Lung cancer, known for its high mortality rate and late-stage detection, has seen significant improvements with AI-powered imaging and predictive analytics, enabling earlier and more accurate diagnosis. This segmentation reflects the broad and expanding role of AI across various cancer types, driving the growth of the market by offering improved diagnostic accuracy, efficiency, and patient outcomes.

**U.S. Artificial Intelligence in Cancer Diagnostics Market, By End-Users**

* **Hospital**
* **Surgical centers & Medical Institute**
* **Others**

The U.S. Artificial Intelligence in Cancer Diagnostics Market is segmented by end-users into hospitals, surgical centers & medical institutes, and others. Hospitals represent the largest share of the market, driven by their access to advanced diagnostic infrastructure, electronic health records, and multidisciplinary care teams. Surgical centers and medical institutes are also embracing AI, particularly in preoperative planning and precision diagnostics. it helps clinicians to make data-driven decisions and personalize treatment A close-up of hands holding a tablet and a pen

Description automatically generatedstrategies. Together, these end-users are accelerating the growth of AI adoption in cancer diagnostics, making high-quality, timely, and personalized cancer care more achievable across the U.S. healthcare system.

**Key Players**

The “U.S. Artificial Intelligence in Cancer Diagnostics Market " study report will provide valuable insight emphasizing the U.S market. The major players in the market are Abbott, Dexcom Inc., Medtronic plc, 3M Company, Epicore Biosystems, GE Healthcare, Boston Scientific Corporation, iRhythm Technologies, Inc., Insulet Corporation, Gentag, Inc., Guardant Health, Tempus AI, Varian Medical Systems, PathAI, Zebra Medical Vision, CureMetrix, Freenome among others. Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis.

**Key Developments**

* In October 2024, Microsoft introduced significant upgrades to its Microsoft Cloud for Healthcare. It is designed to elevate patient care experiences, strengthening team collaboration, and empowering healthcare professionals with advanced digital tools.
* In July 2024, Guardant Health secured FDA approval for its Shield blood test, an AI-driven, non-invasive tool that detects colorectal cancer with 83% sensitivity. This innovative test presents a more accessible and patient-friendly alternative to conventional screening approaches.

**Market Attractiveness**

The image of market attractiveness provided further helps to get information about the region leading in the U.S. Artificial Intelligence in Cancer Diagnostics Market. We cover the major impacting factors driving the industry growth in the given region.

**Porter’s Five Forces**

A close-up of hands holding a tablet and a pen

Description automatically generatedThe image provided would further help to get information about Porter's five forces framework providing a blueprint for understanding the behavior of competitors and a player's strategic positioning in the respective industry. Porter's five forces model can be used to assess the competitive landscape in the U.S. Artificial Intelligence in Cancer Diagnostics Market, gauge the attractiveness of a particular sector, and assess investment possibilities.

A close-up of hands holding a tablet and a pen

Description automatically generatedTABLE OF CONTENT

1 **INTRODUCTION OF U.S. ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET**

* 1. Overview of the market
  2. Scope of report
  3. Assumptions

1. **EXECUTIVE SUMMARY**
2. **RESEARCH METHODOLOGY**
   1. Data Mining
   2. Validation
   3. Primary Interviews
   4. List of Data sources
3. **U.S. ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET OUTLOOK**
   1. Overview
   2. Market Dynamics
      1. Drivers
      2. Restrains
      3. Opportunities
      4. Trends
   3. Portes Five FORCE Model
   4. Value Chain Analysis

**5 U.S. ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET, BY PATCHES**

5.1 Overview

5.2 Software solution

A close-up of hands holding a tablet and a pen

Description automatically generated5.3 Hardware

5.4 Services

**6 U.S. ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE**

6.1 Overview

6.2 Brain tumor

6.3 Breast Cancer

6.4 Lung Cancer

6.5 Colorectal Cancer

6.6 Prostate Cancer

6.7 Others

**7 U.S. ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET, BY END-USERS**

7.1 Overview

7.2 Hospitals

7.3 Surgical centres & Medical Institute

7.4 Others

1. **U.S. ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET COMPETITIVE LANDSCAPE**
   1. Overview
   2. Company Market Ranking
   3. Key Developments Strategies
2. **COMPANY PROFILES**
   1. **Abbott**
      1. Overview
      2. A close-up of hands holding a tablet and a pen

         Description automatically generatedFinancial Performance
      3. Product Outlook
      4. Key developments
   2. **Dexcom Inc**
      1. Overview
      2. Financial Performance
      3. Product Outlook
      4. Key developments
   3. **Medtronic plc**
      1. Overview
      2. Financial Performance

9.3.3 Product Outlook

9.3.4 Key developments

* 1. **3M Company.**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  2. **Epicore Biosystems**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  3. **GE Healthcare**
     1. Overview
     2. A close-up of hands holding a tablet and a pen

        Description automatically generatedFinancial Performance
     3. Product Outlook
     4. Key developments
  4. **Boston Scientific Corporation**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  5. **iRhythm Technologies, Inc**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments

* 1. **Insulet Corporation.**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  2. **Gentag**, **Inc.**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  3. **Guardant Health**
     1. Overview
     2. A close-up of hands holding a tablet and a pen

        Description automatically generatedFinancial Performance
     3. Product Outlook
     4. Key developments
  4. **Tempus AI**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  5. **Varian Medical Systems**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  6. **PathAI**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  7. **Zebra Medical Vision**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  8. **CureMetrix**
     1. Overview
     2. Financial Performance
     3. A close-up of hands holding a tablet and a pen

        Description automatically generatedProduct Outlook
     4. Key developments
  9. **Freenome**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments

1. **KEY DEVELOPMENTS**
   1. Product Launches/Developments
   2. Merges and Acquisitions
   3. Business Expansions
   4. Partnerships and Collaborations
2. **Appendix**

11.1 Related Research